Vera Therapeutics, Inc. (VERA) Form 8-K — Jul 9, 2026
Vera Therapeutics announced that William Turner will step down as Chief Regulatory Officer on August 3, 2026, transitioning to a Special Advisor for Regulatory Affairs role. Nancy Bowman, M.D., Ph.D., will succeed Turner as the new Chief Regulatory Officer effective the same date.
Price after filing
1 day: -1.1%7 days: -7.8%30 days: -22.5%
Close on the filing date to close N calendar days later (from $42.45). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.